The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| DICERNA PHARMACEUTICALS INC | COM | 253031108 | 130,828 | 8,930,237 | SH | SOLE | 8,930,237 | 0 | 0 | ||
| MARINUS PHARMACEUTICALS INC | COM | 56854Q101 | 21,079 | 5,042,735 | SH | SOLE | 5,042,735 | 0 | 0 | ||
| INFLARX NV | COM | N44821101 | 27,688 | 732,670 | SH | SOLE | 732,670 | 0 | 0 | ||
| SOLID BIOSCIENCES INC | COM | 83422E105 | 18,303 | 1,989,444 | SH | SOLE | 1,989,444 | 0 | 0 | ||
| APTINYX INC | COM | 03836N103 | 9,012 | 2,225,092 | SH | SOLE | 2,225,092 | 0 | 0 | ||
| REPLIMUNE GROUP INC | COM | 76029N106 | 43,209 | 2,838,968 | SH | SOLE | 2,838,968 | 0 | 0 | ||